沙美特罗替卡松联合孟鲁司特钠治疗支气管哮喘患者的效果分析  

Effect Analysis of Salmeterol and Fluticasone Combined with Montelukast Sodium in the Treatment of Patients with Bronchial Asthma

作　　者：刘爱环[1] 李树云 LIU Aihuan;LI Shuyun(Department of Respiratory Medicine,Shouguang People’s Hospital,Weifang 261000,China;Department of Critical Care Medicine,Shouguang People’s Hospital,Weifang 261000,China)

机构地区：[1]山东省寿光市人民医院呼吸内科,山东潍坊261000 [2]山东省寿光市人民医院重症医学科,山东潍坊261000

出　　处：《中国伤残医学》2025年第5期51-54,共4页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探究沙美特罗替卡松(SFC)与孟鲁司特钠(MK)联合治疗支气管哮喘(BA)的效果。方法:选取2022年1月—2023年12月寿光市人民医院收治的78例BA患者为研究对象,依据随机数表法将其分为对照组及研究组,每组39例。对照组采用SFC治疗,研究组在对照组基础上采用MK治疗。两组均治疗3个月。对比两组炎性因子水平、肺功能及不良反应发生情况。结果:治疗后,研究组的超敏C反应蛋白、白细胞介素-4、白细胞介素-5水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组的第1秒用力呼气容积、用力肺活量及一秒率均高于对照组,差异均有统计学意义(P<0.05)。研究组的不良反应发生率为12.82%,高于对照组的5.13%,但差异无统计学意义(P>0.05)。结论:SFC联合MK治疗BA相较于单独使用SFC,能更有效地降低患者的血清炎性因子水平,改善其呼吸功能,且安全性良好。Objective:To investigate the effect of Salmeterol Fluticasone(SFC)combined with Montelukast Sodium(MK)on bronchial asthma(BA).Methods:A total of 78 BA patients admitted to Shouguang People’s Hospital from January 2022 to December 2023 were selected as the study objects and were divided into a control group and a study group according to random number table method,with 39 cases in each group.The control group was treated with SFC,and the study group was treated with MK based on the control group.Both groups were treated 3 months.The levels of inflammatory factors,lung function and occurrence of adverse reactions were compared between the two groups.Results:After treatment,the levels of hypersensitive C-reactive protein,interleukin-4 and interleukin-5 in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the forced expiratory volume in one second,forced vital capacity and one-second rate of the study group were higher than those of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 12.82%,which was higher than 5.13%in the control group,but there was no statistical significance(P>0.05).Conclusion:Compared with SFC alone,SFC combined with MK in the treatment of BA can more effectively reduce the level of serum inflammatory factors and improve the respiratory function of patients with good safety.

关 键 词：支气管哮喘 沙美特罗替卡松 孟鲁司特钠 炎性因子 呼吸功能 

分 类 号：R562.25[医药卫生—呼吸系统]